XWELL (XWEL) Expected to Announce Earnings on Monday

XWELL (NASDAQ:XWEL) is expected to issue its Q1 2026 resultson Monday, May 18th. Analysts expect the company to announce earnings of ($1.00) per share and revenue of $2.3710 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 21, 2026 at 4:00 PM ET.

XWELL (NASDAQ:XWEL) last released its quarterly earnings results on Wednesday, April 1st. The company reported ($3.29) earnings per share for the quarter. XWELL had a negative net margin of 58.17% and a negative return on equity of 352.37%. The company had revenue of $7.15 million during the quarter.

XWELL Price Performance

Shares of NASDAQ:XWEL opened at $1.47 on Monday. XWELL has a 12-month low of $0.26 and a 12-month high of $2.20. The stock has a market cap of $11.66 million, a PE ratio of -0.29 and a beta of 1.01. The business has a 50 day moving average of $1.28 and a 200-day moving average of $0.86.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on XWEL shares. Weiss Ratings upgraded XWELL from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. Wall Street Zen upgraded shares of XWELL from a “sell” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

XWELL Company Profile

XWELL, Inc provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels.